Discovery of selective hydroxamic acid inhibitors of tumor necrosis factor-alpha converting enzyme

Bioorg Med Chem Lett. 2001 Nov 19;11(22):2907-10. doi: 10.1016/s0960-894x(01)00603-5.

Abstract

Modification of the P(1)' substituent of macrocyclic matrix metalloproteinase (MMP) inhibitors provided compounds that are selective for inhibition of tumor necrosis factor-alpha converting enzyme (TACE) over MMP-1 and MMP-2. Several analogues potently inhibited the release of TNF-alpha in a THP-1 cellular assay. Compounds containing a trimethoxyphenyl group in the P(1)' substituent demonstrated TACE selectivity across several series of hydroxamate-based inhibitors.

MeSH terms

  • ADAM Proteins
  • ADAM17 Protein
  • Enzyme Inhibitors / chemical synthesis*
  • Enzyme Inhibitors / pharmacology
  • Hydroxamic Acids / chemical synthesis*
  • Hydroxamic Acids / pharmacology
  • Metalloendopeptidases / antagonists & inhibitors*
  • Structure-Activity Relationship
  • Tumor Necrosis Factor-alpha / metabolism

Substances

  • Enzyme Inhibitors
  • Hydroxamic Acids
  • Tumor Necrosis Factor-alpha
  • ADAM Proteins
  • Metalloendopeptidases
  • ADAM17 Protein